Eli Lilly’s $2.8 bn purchase of AtaiBeckley adds psychedelic candidate BPL‑003, sparking optimism for broader mental‑health drug pipeline

Eli Lilly announced it has acquired AtaiBeckley for $2.8 billion, bringing the privately held biotech’s lead psychedelic program into its portfolio.

The deal gives Lilly access to BPL‑003, an intranasal formulation of 5‑MeO‑DMT that showed statistically significant improvement in a phase‑2b trial for patients with treatment‑resistant depression.

Industry analysts said the acquisition could act as a catalyst for the broader psychedelics sector, noting the large unmet need in depression and the benefit of having multiple therapeutic options.

The move follows a recent wave of M&A activity at Lilly and comes after earlier setbacks in the field, such as the FDA advisory committee’s rejection of an MDMA therapy in 2024, but experts remain optimistic that success by one company will ease the path for others.